Personalisierte Therapie des Lungenkarzinoms – Stand und Herausforderungen

Abstract

So called „personalized therapy“ has revolutionized the care of non-small cell lung cancer (NSCLC). The discovery of more and more driver mutations in NSCLC has led to a molecular defined sub classification of lung cancer patients. For four driver mutations (EGFR^mut, ALK^transl, ROS1^transl, BRAF-V600^mut) firstline approved drugs are available and became the treatment of choice. Further drugs are in clinical development or can be used as off-label treatment. The emergence of resistance under targeted therapy, the development of new drugs for further driver mutations and the broad implementation of molecular diagnostics for all lung cancer patients are future challenges.

Die „personalisierte Therapie“ hat die Versorgung von Patienten mit fortgeschrittenem, nicht-kleinzelligem Lungenkarzinom (NSCLC) revolutioniert. Die Entdeckung sogenannter Treibermutationen – d. h. Genveränderungen, die für die maligne Transformation der Lungenkrebszellen verantwortlich sind – hat zu einer zunehmenden molekularen Subklassifizierung des NSCLC und einer molekular gesteuerten Diversifizierung der Therapie geführt.

Schlüsselwörter

Nicht-kleinzelliges Lungenkarzinom (NSCLC) - personalisierte Therapie - molekulare Diagnostik

Key words

non-small cell lung cancer (NSCLC) - targeted therapy, molecular diagnostic

• Literatur

• 1 Schiller JH, Harrington D, Belani CP. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 2: 92-98
• 2 Barlesi F, Mazieres J, Merlio JP. et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; 387: 1415-1426
• 3 Mok TS, Wu YL, Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957
• 4 The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med 2013; 209: 209ra153
• 5 Solomon BJ, Mok T, Kim DW. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-2177
• 6 Kostenko A, Michels SYF, Fassunke J. et al. Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer: Results of the German Network Genomic Medicine. J Clin Oncol 2016 15_suppl: 9085-9085
• 7 Scheffler M, Schultheis A, Teixido C. et al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget 2015; 12: 10577-10585
• 8 Shaw AT, Ou SH, Bang YJ. et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371: 1963-1971
• 9 Planchard D, Besse B, Groen HJ. et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 2016; 17: 984-993
• 10 Yu HA, Arcila ME, Rekhtman N. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-2247
• 11 Mok TS, Wu YL, Ahn MJ. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629-640
• 12 Gainor JF, Dardaei L, Yoda S. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016; 6: 1118-1133
• 13 Scheffler M, Merkelbach-Bruse S, Bos M. et al. Spatial tumor heterogeneity in lung cancer with acquired epidermal growth factor receptor-tyrosine kinase inhibitor resistance: Targeting high-level MET-amplification and EGFR T790M mutation occurring at different sites in the same patient. J Thorac Oncol 2015; 6: e40-e43
• 14 Shaw AT, Peters S, Mok TS. et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. J Clin Oncol 2017 35. (suppl; abstr LBA9008)
• 15 Awad MM, Leonardi GC, Kravets S. et al. Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). J Clin Oncol 2017 35. (suppl; abstr 8511)
• 16 Drilon AE, Camidge DR, Ou SHI. et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol 2016 15_suppl: 108 – 108
• 17 Drilon A, Siena S, Ou SI. et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372–001 and STARTRK-1). Cancer Discov 2017; 7: 400-409
• 18 Gatzemeier U, Groth G, Butts C. et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 1: 19-27
• 19 Wang R, Hu H, Pan Y. et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012; 35: 4352-4359
• 20 Drilon A, Wang L, Hasanovic A. et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013; 3: 630-635
• 21 Tabernero J, Bahleda R, Dienstmann R. et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol 2015; 33: 3401-3408
• 22 Nogova L, Sequist LV, Perez GarciaJM. et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1–3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: Results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol 2017; 35: 157-165
• 23 Jänne PA, Shaw AT, Pereira JR. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14: 38-47
• 24 Jänne PA, van den Heuvel MM, Barlesi F. et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. JAMA 2017; 317: 1844-1853
• 25 Blumenschein Jr GR, Smit EF, Planchard D. et al. A randomized phase II study of the MEK1 / MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)dagger. Ann Oncol 2015; 26: 894-901
• 26 Scheffler M, Ihle MA, Hein R. et al. Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background. J Clin Oncol 2016 15. 15_suppl: 9018 – 9018
• 27 Wan JC, Massie C, Garcia-Corbacho J. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017; 17: 223-238
• 28 Brahmer J, Reckamp KL, Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
• 29 Borghaei H, Paz-Ares L, Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
• 30 Scheel AH, Dietel M, Heukamp LC. et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016; 29: 1165-1172
• 31 Reck M, Rodriguez-Abreu D, Robinson AG. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-1833
• 32 Rizvi NA, Hellmann MD, Snyder A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128
• 33 Carbone DP, Reck M, Paz-Ares L. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017; 376: 2415-2426